Remove 2019 Remove Individual Remove Provider Remove Supply Chain
article thumbnail

Is 2023 the Year for OTC Naloxone?

FDA Law Blog

sales of naloxone from a wholesale distributor to a harm reduction program) from certain requirements under the Drug Supply Chain Security Act. Many states already have standing orders that allow for the dispensing of naloxone without an individual prescription and other public health initiatives to increase naloxone access.

article thumbnail

Analysis of primary care prescription trends in England during the COVID-19 pandemic compared against a predictive model

BMJ

In the United Kingdom (UK), primary care practitioners are the first-line clinicians which most patients encounter, providing initial assessment and treatment of a wide variety of conditions. Over one billion prescriptions per year are signed in the UK by these general practitioners (GPs) in primary care.

article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law Blog

A May 2019 CMS final rule that would have required drug TV advertisements to disclose the WAC of the drug was challenged by a group of pharmaceutical companies and vacated on statutory grounds by the D.C. Increase Transparency and Strengthen Supply Chain and Research Capacity. ADMINISTRATIVE ACTIONS.